Toxin for Treating Raynaud Conditions in Hands (The TORCH Study): A Systematic Review and Meta-analysis
- PMID: 38881966
- PMCID: PMC11177805
- DOI: 10.1097/GOX.0000000000005885
Toxin for Treating Raynaud Conditions in Hands (The TORCH Study): A Systematic Review and Meta-analysis
Abstract
Background: Raynaud disease of the hands is a complex disorder resulting in inappropriate constriction and/or insufficient dilation in microcirculation. There is an emerging role for botulinum toxin type A (BTX-A) in the treatment armamentarium for refractory Raynaud disease. The aim of this systematic review was to critically evaluate the management of primary and secondary Raynaud disease treated with BTX-A intervention.
Methods: We performed a Preferred Reporting Items for Systematic Reviews and Meta-Analyses-compliant systematic review of clinical studies assessing treatment of primary or secondary Raynaud disease with BTX-A by searching Ovid MEDLINE and Embase databases from inception to first August 2023. The review protocol was prospectively registered on the PROSPERO database (CRD42022312253).
Results: Our search strategy identified 288 research articles, of which 18 studies [four randomized controlled trials (RCTs), two non-RCTs, five case series, and seven retrospective cohort studies] were eligible for analysis. Meta-analysis demonstrated that the probability of pain visual analog scale score improvement with BTX-A intervention was 81.95% [95% confidence interval (74.12-87.81) P = 0.19, heterogeneity I 2 = 26%] and probability of digital ulcer healing was 79.37% [95% confidence interval (62.45-89.9) P = 0.02, heterogeneity I 2 = 56%].
Conclusions: Delivery of BTX-A to digital vessels in the hand may be an effective management strategy for primary and secondary Raynaud disease. A definitive, appropriately-powered RCT with objective functional and patient-reported outcome measures is required to accurately assess and quantify the efficacy of BTX-A in Raynaud disease of the hands.
Copyright © 2024 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons.
Conflict of interest statement
The authors have no financial interest to declare in relation to the content of this article.
Figures
Similar articles
-
Botulinum Toxin Type A for Diabetic Peripheral Neuropathy Pain: A Systematic Review and Meta-Analysis.J Pain Res. 2021 Dec 16;14:3855-3863. doi: 10.2147/JPR.S340390. eCollection 2021. J Pain Res. 2021. PMID: 34938114 Free PMC article. Review.
-
Botulinum Toxin A Plays an Important Role in the Placement of Implants Deep Within the Pectoralis Major Muscle for Mammaplasty: A Systematic Review and Meta-analysis.Aesthetic Plast Surg. 2018 Dec;42(6):1519-1530. doi: 10.1007/s00266-018-1203-1. Epub 2018 Aug 6. Aesthetic Plast Surg. 2018. PMID: 30083802
-
The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Arthritis Rheumatol. 2017 Aug;69(8):1661-1669. doi: 10.1002/art.40123. Epub 2017 Jun 26. Arthritis Rheumatol. 2017. PMID: 28426903 Free PMC article. Clinical Trial.
-
Efficacy and safety of botulinum toxin for treating motor dysfunction in patients with Parkinson's disease: a systematic review and meta-analysis.BMJ Open. 2023 Jun 16;13(6):e060274. doi: 10.1136/bmjopen-2021-060274. BMJ Open. 2023. PMID: 37328181 Free PMC article.
-
Botulinum Toxin-A Injection in Chronic Pelvic Pain Syndrome Treatment: A Systematic Review and Pooled Meta-Analysis.Toxins (Basel). 2022 Jan 1;14(1):25. doi: 10.3390/toxins14010025. Toxins (Basel). 2022. PMID: 35051002 Free PMC article.
Cited by
-
Botulinum Toxin for the Treatment of Raynaud's Conditions of the Hand: Clinical Practice Updates and Future Directions.Toxins (Basel). 2024 Nov 1;16(11):472. doi: 10.3390/toxins16110472. Toxins (Basel). 2024. PMID: 39591227 Free PMC article. Review.
-
The Effects of Botulinum Toxin on Vascular Diameter: A Preliminary Report.J Cosmet Dermatol. 2025 Mar;24(3):e70113. doi: 10.1111/jocd.70113. J Cosmet Dermatol. 2025. PMID: 40071587 Free PMC article. No abstract available.
References
-
- Reggi M, Boccalon H. Le dossier informatisé en pathologie vasculaire. IV. “Gestion informatique” du phénomène de Raynaud [Computerized records in vascular pathology. IV. Computer-assisted management in Raynaud’s phenomenon]. J Mal Vasc. 1986;11:137–139. - PubMed
-
- Bakst R, Merola JF, Franks AG, Jr, et al. . Raynaud’s phenomenon: pathogenesis and management. J Am Acad Dermatol. 2008;59:633–653. - PubMed
-
- García-Carrasco M, Jiménez-Hernández M, Escárcega RO, et al. . Treatment of Raynaud’s phenomenon. Autoimmun Rev. 2008;8:62–68. - PubMed
-
- Valdovinos ST, Landry GJ. Raynaud syndrome. Tech Vasc Interv Radiol. 2014;17:241–246. - PubMed
LinkOut - more resources
Full Text Sources